Conflict of Interest in the Debate over Calcium-Channel Antagonists
Authors:
- Grace ChuaGCGrace Chua
- Keith O'RourkeKOKeith O'Rourke
- Allan S. DetskyADAllan S. Detsky
- 8 January 1998
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 338 (2) , 101-106
Abstract
Physicians' financial relationships with the pharmaceutical industry are controversial because such relationships may pose a conflict of interest. It is unknown to what extent industry support of medical education and research influences the opinions and behavior of clinicians and researchers. The recent debate over the safety of calcium-channel antagonists provided an opportunity to examine the effect of financial conflicts of interest.Keywords
This publication has 62 references indexed in Scilit:
- Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonistsThe American Journal of Cardiology, 1996
- Antihypertensive Therapy: Safety and Efficacy of Drugs and PublicationsHypertension, 1996
- Myocardial infarction associated with antihypertensive drug therapyJAMA, 1996
- A delayed answer to the calcium blocker questionJACC, 1996
- Do calcium antagonists cause myocardial infarction?The American Journal of Cardiology, 1996
- Safety of calcium antagonistsThe Lancet, 1995
- Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con sideArchives of internal medicine (1960), 1995
- Calcium antagonists should continue to be used for first-line treatment of hypertensionArchives of internal medicine (1960), 1995
- Bayer accused of disinformationThe Lancet, 1995
- Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet testedJAMA, 1995